Role of transrectal ultrasound and MRI in the diagnosis and localisation of carcinoma prostate - A comparison of diagnostic efficacy of trus versus MRI

Abstract

In this study, we wanted to correlate the findings of TRUS and MRI with regard to the diagnosis and localization of carcinoma prostate and local staging of carcinoma prostate. Our study included 43 men, with age ranging from 49 to 76 years. They underwent TRUS, MRI and TRUS guided twelve core biopsies after being suspected with prostate cancer based on high PSA values (greater than 4.0 ng /ml) or abnormal DRE findings. This study was conducted from April 2018 -June 2019. Imaging findings were confirmed with histopathology. TRUS used for the detection of malignancy had sensitivity, specificity, PPV and NPV as 69.70%, 80 %, 92% and 44.44 % respectively. The values were 63.16%, 83.33%, 75.00%, and 74.07% for the sensitivity, specificity, PPV and NPV of TRUS respectively for the detection of ECE. rnFor the detection of malignancy, the sensitivity, specificity, PPV and NPV of MRI was 87.88%, 70%, 90.63% and 63.64% respectively and 85.71%, 89.66%, 80.00% and 92.86% for the sensitivity, specificity, PPV and NPV of MRI respectively for detection of SVI. For detection of extracapsular extension (ECE), MRI had sensitivity, specificity, PPV and NPV of 78.95%, 83.33%, 78.95% and 83.33% respectively. When compared to TRUS, MRI is more useful in the diagnosis and accurate staging of prostate cancer. MRI can improve the false-negative biopsies resulting due to the inability of TRUS in detection of abnormal areas.